Mistra (Dienogest, Ethinylestradiol)

The combination works by suppressing the hypothalamic‑pituitary‑ovarian axis, preventing the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, thereby inhibiting ovulation. Additionally, it thickens cervical mucus and alters the endometrial lining, creating an environment hostile to fertilisation and implantation.

The specific dosing regimen for Mistra is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for a 21‑day active tablet phase followed by a hormone‑free interval, but the exact schedule should be confirmed with the prescriber.

Mistra is intended for use only when pregnancy is not desired; it should be discontinued if pregnancy occurs. Safety during pregnancy has not been established, and the product is generally not recommended for breastfeeding women without medical advice, as hormonal exposure may affect milk production.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mistra. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Mistra contains the progestogen dienogest combined with ethinylestradiol, offering a low‑dose estrogen component and a progestogen with a favorable bleeding profile. Compared with older formulations that use levonorgestrel or norethisterone, dienogest may provide better cycle control and lower androgenic side effects, though efficacy in preventing pregnancy remains comparable across approved combined oral contraceptives.

Store Mistra at below 25 °C in its original blister pack, protecting it from moisture and direct sunlight. Keep the tablets out of reach of children and do not use them after the expiration date printed on the packaging. No refrigeration is required for this oral tablet.

Mistra is taken orally, usually once each day at the same time, with or without food. The typical regimen involves a series of active tablets followed by a hormone‑free interval, after which a new pack is started. Patients should follow the prescribing clinician’s instructions for the exact schedule.

Serious but rare risks include venous thromboembolism, arterial thrombosis, myocardial infarction, stroke, and hepatic adenoma. Women with a history of clotting disorders, smoking, hypertension, or certain cardiovascular conditions should be evaluated carefully before initiating therapy. Immediate medical attention is required if symptoms such as chest pain, leg swelling, or severe headache occur.

Mistra is contraindicated in women with known or suspected pregnancy, active or past thromboembolic disease, uncontrolled hypertension, certain liver tumors, or a history of estrogen‑dependent malignancies. It should also be avoided in individuals who are breastfeeding without medical guidance, and in those with known hypersensitivity to dienogest, ethinylestradiol, or any tablet excipients.